FDA allows use of more molnupiravir brands | Inquirer News

FDA allows use of more molnupiravir brands; Pfizer seeks nod for Paxlovid

By: - Reporter / @DYGalvezINQ
/ 01:40 AM February 08, 2022

Photo of FDA building for story: FDA allows use of more molnupiravir brands; Pfizer seeks nod for Paxlovid

The main office of the Food and Drugs Administration in Muntinlupa City. (Photo from the FDA Facebook page)

MANILA, Philippines — The Food and Drug Administration (FDA) has so far granted an emergency use authorization (EUA) to six brands of the anti-COVID drug molnupiravir.

In a taped briefing with President Rodrigo Duterte on Monday, FDA Deputy Director Oscar Gutierrez said FDA has issued an EUA for the following brands, with manufacturers in parentheses:

ADVERTISEMENT
  • Molnarz (Faberco)
  • Molnaflu (Medethix)
  • Auxilto (German Quality Pharma)
  • Molxvir (Sun Pharma)
  • Molnatris (Mykan)
  • Molnupiravir Generic (Lloyd Laboratories/Dr. Zen’s Research)

According to Gutierrez, the FDA granted an EUA on Jan, 28 to local firm Lloyd Laboratories for the 200-mg and 400-mg molnupiravir capsules.

FEATURED STORIES

“The FDA findings are clear that it has the capacity to produce molnupiravir capsules under current good manufacturing practices and molnupiravir meets the safety and quality standard as an investigatory COVID-19 drug,” he said, speaking in a mix of English and Filipino.

Meanwhile, Pfizer had already applied for an EUA for its anti-viral pill Paxlovid, according to Gutierrez.

The application is currently undergoing evaluation, he said.

The FDA will continue to receive and approve compassionate special permit applications within the next three months to augment the supply of investigatory COVID-19 drugs in the Philippines.

Gutierrez added that the FDA had approved another brand of self-administered COVID-19 antigen test kits.

With the new approved brand, there are currently three brands of antigen self-test kits that the public may buy in accredited outlets nationwide.

ADVERTISEMENT

READ: Anti-COVID drug molnupiravir shelf life extension to 12 months gets FDA OK

ATM
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, EUA, FDA, molnupiravir

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.